Equities analysts expect CONMED Co. (NASDAQ:CNMD) to report earnings of $0.43 per share for the current quarter, according to Zacks. Two analysts have made estimates for CONMED’s earnings. The lowest EPS estimate is $0.42 and the highest is $0.43. CONMED reported earnings of $0.38 per share in the same quarter last year, which indicates a positive year-over-year growth rate of 13.2%. The firm is scheduled to announce its next quarterly earnings results on Wednesday, April 25th.
On average, analysts expect that CONMED will report full year earnings of $2.14 per share for the current year, with EPS estimates ranging from $2.14 to $2.15. For the next year, analysts expect that the business will post earnings of $2.38 per share, with EPS estimates ranging from $2.36 to $2.40. Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for CONMED.
CONMED (NASDAQ:CNMD) last announced its quarterly earnings results on Wednesday, January 31st. The medical technology company reported $0.69 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.04. CONMED had a net margin of 6.97% and a return on equity of 9.15%. The company had revenue of $222.60 million for the quarter, compared to analyst estimates of $212.17 million. During the same quarter in the prior year, the business posted $0.54 EPS. CONMED’s quarterly revenue was up 9.1% on a year-over-year basis.
In other CONMED news, EVP Luke A. Pomilio sold 29,363 shares of the stock in a transaction on Thursday, November 9th. The shares were sold at an average price of $50.70, for a total value of $1,488,704.10. Following the completion of the sale, the executive vice president now directly owns 45,486 shares of the company’s stock, valued at approximately $2,306,140.20. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Jo Ann Golden sold 3,000 shares of the stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $63.90, for a total transaction of $191,700.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 50,386 shares of company stock valued at $2,822,702. 2.62% of the stock is owned by insiders.
Institutional investors have recently modified their holdings of the business. Public Employees Retirement System of Ohio boosted its holdings in CONMED by 3.3% in the 2nd quarter. Public Employees Retirement System of Ohio now owns 2,022 shares of the medical technology company’s stock valued at $103,000 after purchasing an additional 64 shares during the period. Quantbot Technologies LP bought a new stake in CONMED in the 3rd quarter valued at $133,000. Piedmont Investment Advisors LLC bought a new stake in CONMED in the 2nd quarter valued at $273,000. Crossmark Global Holdings Inc. bought a new stake in CONMED in the 3rd quarter valued at $281,000. Finally, OxFORD Asset Management LLP bought a new stake in CONMED in the 3rd quarter valued at $294,000. 99.21% of the stock is owned by hedge funds and other institutional investors.
Shares of CONMED (NASDAQ:CNMD) opened at $60.78 on Wednesday. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.49 and a current ratio of 2.56. The stock has a market cap of $1,721.01, a price-to-earnings ratio of 32.43, a P/E/G ratio of 2.50 and a beta of 0.74. CONMED has a 1-year low of $39.74 and a 1-year high of $64.99.
ILLEGAL ACTIVITY NOTICE: “Brokerages Anticipate CONMED Co. (CNMD) Will Announce Earnings of $0.43 Per Share” was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/02/07/brokerages-anticipate-conmed-co-cnmd-will-announce-earnings-of-0-43-per-share.html.
CONMED Corporation is a medical technology company. The Company is engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. The Company provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CONMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED and related companies with MarketBeat.com's FREE daily email newsletter.